Increasingly, open-source–based alliances seek to provide broad access to data, research-based tools, preclinical samples and downstream compounds. The challenge is how to create value from open-source biopharmaceutical innovation. This value creation may occur via transparency and usage of data across the biopharmaceutical value chain as stakeholders move dynamically between open source and open innovation.
It is the author’s opinion that the assessment of when and how value creation will occur, through open-source biopharmaceutical innovation, is paramount. The key is to determine the metrics of value creation and the necessary technological, educational and legal frameworks to support the downstream outcomes of now big data-based open-source initiatives. The continued focus on the early-stage value creation is not advisable. Instead, it would be more advisable to adopt an approach where stakeholders transform open-source initiatives into open-source discovery, crowdsourcing and open product development partnerships on the same platform.
Read More: http://informahealthcare.com/doi/abs/10.1517/17460441.2014.905539?af=RAstraZeneca unit debuts new open innovation platform for partnering programsMarch 25 2014
The Pharma Letter
Anglo-Swedish drug major AstraZeneca’s IMED Biotech unit has launched a dedicated web site to support an increasing range of open innovation programs and to better facilitate research collaborations with academia, industry, non-governmental organizations (NGOs) and governments.
Global Innovation Index 2013
INSEAD-WIPO-Cornell University rank 142 countries on their innovation capabilities. Sixth annual index reshuffles the top ten and shows gap widening between rich and poor countries.
University Partnerships in the Era of University Innovation Merchants– a Practical Guide for Companies Continue Reading More Innovation News and Blogs...
Assess the opportunities and challenges of engaging in open innovation with universities.